Drug Profile

Opemalirsen - AstraZeneca

Alternative Names: AZD-2373; ION-532; IONIS-AZ5-2.5Rx

Latest Information Update: 08 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ionis Pharmaceuticals
Developer AstraZeneca
Class Antisense oligonucleotides; Urologics
Mechanism of Action Gene silencing

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Kidney disorders

Most Recent Events

25 Feb 2026 Opemalirsen - AstraZeneca receives Fast Track designation for Kidney disorders [SC,Injection] in USA
18 Aug 2025 AstraZeneca initiates phase-I pharmacokinetics and safety trial in USA (SC, injection) (NCT07154901)
28 May 2025 No recent reports of development identified for phase-I development in Kidney-disorders(In volunteers) in USA (SC, Injection)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com